SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 13.41 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 32.68 |
| Book Value / Share | 0.97 |
| Price / Book | n/a |
| NCAV ($M) | -14.78 |
| NCAV / Share | -0.44 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -0.35 |
| Return on Equity (ROE) | -0.56 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.85 |
| Current Ratio | 1.01 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 12.50 |
| Assets | 59.96 |
| Liabilities | 27.29 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Charmquark TWEE | 5.80 | -41.62 | |
| 13G | Ingalls & Snyder Llc | 5.01 | 25.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 247,930 | 516,323 | 48.02 | |
| 145,644 | 519,062 | 28.06 | |
| 341,469 | 909,572 | 37.54 | |
| 472,042 | 1,365,655 | 34.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INMB – INmune Bio, Inc. | INO – Inovio Pharmaceuticals, Inc. |
| INTS – Intensity Therapeutics, Inc. | IRD – Opus Genetics, Inc. |
| ITRM – Iterum Therapeutics plc |
Financial data and stock pages provided by
Fintel.io